Risk of recurrence after surgical resection of small-sized invasive lung adenocarcinoma: Analysis based on apoptotic index

Japanese Journal of Thoracic and Cardiovascular Surgery

Volumn 53, Issue 7, 2005, Pages 345-353

  Morio, Atsushi ^a,b,c   Miyamoto, Hideaki ^a   Izumi, Hiroshi ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Kobari General Hospital   (Japan)

^c Kobari General Hospital   (Japan)

Author keywords

Apoptosis; Noguchi's classification; Small sized lung adenocarcinoma

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; PROTEIN P53;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; APOPTOSIS; CANCER CLASSIFICATION; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; NICK END LABELING; PROGNOSIS; REVIEW; RISK ASSESSMENT; STAINING; STATISTICAL ANALYSIS;

EID: 23344434277     PISSN: 13444964     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11748-005-0048-0     Document Type: Review

References (30)

1. Noguchi M, Morikawa A, Kawasaki M, Matsuno Y, Yamada T, Hirohashi S, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 1995; 75: 2844-52.
2. Kawahara K, Iwasaki A, Yoshinaga Y, Shiraishi T, Okabayashi K, Tohchika H, et al. Lymph node metastasis and prognosis in small peripheral non-small-cell lung cancers. Jpn J Thorac Cardiovasc Surg 2000; 48: 618-24.
3. Kerr JF, Wyllie AH, Currie AR. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239-57.
4. Symonds H, Krall L, Remington L, Saenz-Robles M, Lowe S, Jacks T, et al. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 1994; 78: 703-11.
5. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984; 133: 1710-5.
6. Minami K, Saito Y, Imamura H, Okamura A. Prognostic significance of p53, Ki-67, VEGF and Glut-1 in resected stage I adenocarcinoma of the lung. Lung Cancer 2002; 38: 51-7.
7. Hashimoto K, Araki K, Osaki M, Nakamura H, Tomita K, Shimizu E, et al. MCM2 and Ki-67 expression in human lung adenocarcinoma: Prognostic implications. Pathobiology 2004; 71: 193-200.
8. Haitel A, Wiener HG, Migschitz B, Marberger M, Susani M. Proliferating cell nuclear antigen and MIB-1. An alternative to classic prognostic indicators in renal cell carcinomas? Am J Clin Pathol 1997; 107: 229-35.
9. Bancroft CC, Chen Z, Yeh J, Sunwoo JB, Yeh NT, Jackson S, et al. Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 2002; 99: 538-48.
10. Raben D, Helfrich BA, Chan D, Johnson G, Bunn PA Jr. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol 2002; 29 (1 Suppl 4): 37-46.
11. Selvaggi G, Novello S, Torri V, Leonardo E, De Giuli P, Borasio P, et al. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol 2004; 15: 28-32.
12. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambrilla E. Histological Typing of Lung and Pleural Tumors, World Health Organization international histological classification of tumors. Berlin: Springer, 1999.
13. International Union Against Cancer (UICC). TNM Classification of Malignant Tumors, 6th ed. Sobin LH, Wittekind Ch, eds. New York: Wiley-Liss, 2002.
14. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: Implications for a standardized scoring system. Cancer 2001; 92: 1331-46.
15. Arends MJ, McGregor AH, Wyllie AH. Apoptosis is inversely related to necrosis and determines net growth in tumors bearing constitutively expressed myc, ras, and HPV oncogenes. Am J Pathol 1994; 144: 1045-57.
16. Radinsky R, Fidler IJ, Price JE, Esumi N, Tsan R, Petty CM, et al. Terminal differentiation and apoptoses in experimental lung metastases of human osteogenic sarcoma cells by wild type p53. Oncogene 1994; 9: 1877-83.
17. Wheeler JA, Stephens LC, Tornos C, Eifel PJ, Ang KK, Milas L, et al. ASTRO Research Fellowship: Apoptosis as a predictor of tumor response to radiation in stage IB cervical carcinoma. American Society for Therapeutic Radiology and Oncology. Int J Radiat Oncol Biol Phys 1995; 32: 1487-93.
18. Tanaka F, Kawano Y, Li M, Takata T, Miyahara R, Yanagihara K, et al. Prognostic significance of apoptotic index in completely resected non-small-cell lung cancer. J Clin Oncol 1999; 17: 2728-36.
19. Tormanen U, Eerola AK, Rainio P, Vahakangas K, Soini Y, Sormunen R, et al. Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma. Cancer Res 1995; 55: 5595-602.
20. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J; International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350: 351-60.
21. Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, et al.; Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004; 350: 1713-21.
22. Oki E, Sakaguchi Y, Toh Y, Oda S, Maehara Y, Yamamoto N, et al. Induction of apoptosis in human tumour xenografts after oral administration of uracil and tegafur to nude mice bearing tumours. Br J Cancer 1998; 78: 625-30.
23. Morio A, Miyamoto H, Izumi H, Futagawa T, Oh T, Yamazaki A, et al. Enhanced induction of apoptosis in lung adenocarcinoma after preoperative chemotherapy with tegafur and uracil (UFT). Surgery Today 2004; 34: 822-7.
24. Hamada M, Naomoto Y, Fujiwara T, Kamikawa Y, Tanaka N. Suppressed apoptotic induction in esophageal squamous cell carcinomas expressing extensive p53 protein. Jpn J Clin Oncol 1996; 26: 398-404.
25. Kobayashi M, Watanabe H, Ajioka Y, Yoshida M, Hitomi J, Asakura H. Correlation of p53 protein expression with apoptotic incidence in colorectal neoplasia. Virchows Arch 1995; 427: 27-32.
26. Adrain C, Martin SJ. The mitochondrial apoptosome: A killer unleashed by the cytochrome seas. Trends Biochem Sci 2001; 26: 390-7.
27. Minna JD. The molecular biology of lung cancer pathogenesis. Chest 1993; 103 (4 Suppl): 449S-56S.
28. Lee JS, Yoon A, Kalapurakal SK, Ro JY, Lee JJ, Tu N, et al. Expression of p53 oncoprotein in non-small-cell lung cancer: A favorable prognostic factor. J Clin Oncol 1995; 13: 1893-903.
29. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103: 211-25.
30. Meert AP, Martin B, Delmotte P, Berghmans T, Lafitte JJ, Mascaux C, et al. The role of EGF-R expression on patient survival in lung cancer: A systematic review with meta-analysis. Eur Respir J 2002; 20: 975-81.